Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, placebo-controlled trial of troriluzole as adjunctive treatment for obsessive-compulsive disorder
CTR20212534Phase 3Completed
- Sponsor
- BioShin
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Troriluzole adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Change in Yale-Brown Obsessive Compulsive Scale total score at week 10. Started Nov 2022; status: completed.
02
Drugs
troriluzole
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on CTR20212534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212534.